Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studiesHiroaki Akamatsu, Tetsuya Mitsudomi, Yuriko Takeda et al.|Lung Cancer|2025Cited by 2